Neurodevelopmental Outcomes at Age 5 Years After Prophylactic Early High-Dose Recombinant Human Erythropoietin for Neuroprotection in Very Preterm Infants
Giancarlo Natalucci, Beatrice Latal, Brigitte Koller, Christoph M. Rüegger, Beate Sick, Leonhard Held, Jean‐Claude Fauchère, Swiss EPO Neuroprotection Trial Group
Abstract
This study reports 5-year neurodevelopmental outcomes for Swiss children born before 32 weeks’ gestation and randomized at birth to receive early high-dose recombinant human erythropoietin (rhEpo) vs placebo.
Topics & Concepts
MedicineNeuroprotectionErythropoietinRecombinant DNAPediatricsIntensive care medicineInternal medicineBiochemistryGeneChemistryNeonatal and fetal brain pathologyCerebral Palsy and Movement DisordersDialysis and Renal Disease Management